{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:31:49Z","timestamp":1790742709760,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004479","name":"Jiangxi Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["20242BAB25588"],"award-info":[{"award-number":["20242BAB25588"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010847","name":"Jiangxi Province Health Commission","doi-asserted-by":"publisher","award":["202310841"],"award-info":[{"award-number":["202310841"]}],"id":[{"id":"10.13039\/501100010847","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82460680"],"award-info":[{"award-number":["82460680"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82304291"],"award-info":[{"award-number":["82304291"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ejmech.2025.117923","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T12:39:40Z","timestamp":1751373580000},"page":"117923","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Design and synthesis of Riluzole-Ciprofloxacin hybrids as selective MST3 inhibitors for cancer treatment"],"prefix":"10.1016","volume":"297","author":[{"given":"Deping","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuoqi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjin","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxiong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renze","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.117923_bib1","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41573-021-00195-4","article-title":"Kinase drug discovery 20 years after imatinib: progress and future directions","volume":"20","author":"Cohen","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.117923_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107059","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2024 update","volume":"200","author":"Roskoski","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2025.117923_bib3","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/s41573-021-00252-y","article-title":"Trends in kinase drug discovery: targets, indications and inhibitor design","volume":"20","author":"Attwood","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.117923_bib4","doi-asserted-by":"crossref","DOI":"10.1126\/science.aan4368","article-title":"The target landscape of clinical kinase drugs","volume":"358","author":"Klaeger","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.117923_bib5","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nrd.2018.21","article-title":"Kinase inhibitors: the road ahead","volume":"17","author":"Ferguson","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.117923_bib6","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1083\/jcb.201507005","article-title":"MST kinases in development and disease","volume":"210","author":"Thompson","year":"2015","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.117923_bib7","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13008-023-00090-x","article-title":"Molecular mechanisms involved in regulating protein activity and biological function of MST3","volume":"18","author":"Qiu","year":"2023","journal-title":"Cell Div."},{"key":"10.1016\/j.ejmech.2025.117923_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.102961","article-title":"Serine\/threonine-protein kinase STK24 induces tumorigenesis by regulating the STAT3\/VEGFA signaling pathway","volume":"299","author":"Lai","year":"2023","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.117923_bib9","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/8646088","article-title":"STK24 promotes progression of LUAD and modulates the immune microenvironment","volume":"2023","author":"Li","year":"2023","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.ejmech.2025.117923_bib10","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202300397RR","article-title":"STE20-type kinases MST3 and MST4 promote the progression of hepatocellular carcinoma: evidence from human cell culture and expression profiling of liver biopsies","volume":"37","author":"Caputo","year":"2023","journal-title":"FASEB J."},{"key":"10.1016\/j.ejmech.2025.117923_bib11","first-page":"2130","article-title":"The oncogenic role of MST3 in human gastric cancer","volume":"8","author":"Lee","year":"2018","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.117923_bib12","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/cmdc.201600115","article-title":"Discovery of diverse small-molecule inhibitors of Mammalian Sterile20-like kinase 3 (MST3)","volume":"11","author":"Olesen","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2025.117923_bib13","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1021\/acs.jmedchem.3c01980","article-title":"Synthesis of pyrazole-based macrocycles leads to a highly selective inhibitor for MST3","volume":"67","author":"Amrhein","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117923_bib14","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1021\/acs.jmedchem.3c02217","article-title":"Development of selective Pyrido[2,3-d]pyrimidin-7(8H)-one-Based Mammalian STE20-Like (MST3\/4) kinase inhibitors","volume":"67","author":"Rak","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117923_bib15","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3892\/ijo.2021.5275","article-title":"Riluzole: a neuroprotective drug with potential as a novel anti-cancer agent (Review)","volume":"59","author":"Blyufer","year":"2021","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ejmech.2025.117923_bib16","doi-asserted-by":"crossref","first-page":"302","DOI":"10.18632\/oncotarget.28403","article-title":"A phase I trial of riluzole and sorafenib in patients with advanced solid tumors: CTEP #8850","volume":"14","author":"Spencer","year":"2023","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2025.117923_bib17","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3389\/fcell.2020.00454","article-title":"Discovery of a novel hybrid of vorinostat and riluzole as a potent antitumor agent","volume":"8","author":"Xu","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ejmech.2025.117923_bib18","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3109\/14756360903373350","article-title":"Ciprofloxacin: review on developments in synthetic, analytical, and medicinal aspects","volume":"25","author":"Sharma","year":"2010","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117923_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111810","article-title":"Anticancer and antimicrobial effects of novel ciprofloxacin fatty acids conjugates","volume":"185","author":"Chrzanowska","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117923_bib20","doi-asserted-by":"crossref","first-page":"e514","DOI":"10.3324\/haematol.2018.191361","article-title":"Phase 3 results for vosaroxin\/cytarabine in the subset of patients \u226560 years old with refractory\/early relapsed acute myeloid leukemia","volume":"103","author":"Farhad","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.ejmech.2025.117923_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105875","article-title":"Discovery of novel tacrine derivatives as potent antiproliferative agents with CDKs inhibitory property","volume":"126","author":"Liu","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.117923_bib22","doi-asserted-by":"crossref","first-page":"20972","DOI":"10.1039\/D2NJ03591J","article-title":"Discovery of novel and potent tacrine derivatives as CDK2 inhibitors","volume":"46","author":"Huang","year":"2022","journal-title":"New J. Chem."},{"key":"10.1016\/j.ejmech.2025.117923_bib23","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.1021\/jm501853m","article-title":"A survey of the role of noncovalent sulfur interactions in drug design","volume":"58","author":"Beno","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117923_bib24","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1021\/acs.jmedchem.7b01490","article-title":"Adventures in scaffold morphing: discovery of fused ring heterocyclic checkpoint kinase 1 (CHK1) inhibitors","volume":"61","author":"Yang","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117923_bib25","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1021\/jm301891t","article-title":"Discovery of new benzothiazole-based inhibitors of breakpoint cluster region-Abelson kinase including the T315I mutant","volume":"56","author":"Hong","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117923_bib26","doi-asserted-by":"crossref","first-page":"9599","DOI":"10.1021\/acs.jmedchem.4c00724","article-title":"Site-specific antimicrobial activity of a dual-responsive ciprofloxacin prodrug","volume":"67","author":"Ross","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117923_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114187","article-title":"Discovery of a potent and highly selective inhibitor of ataxia telangiectasia mutated and Rad3-Related (ATR) kinase: structural activity relationship and antitumor activity both in vitro and in vivo","volume":"232","author":"Bin","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117923_bib28","article-title":"ZDQ-0620, a novel phosphatidylinositol 3-Kinase inhibitor, inhibits colorectal carcinoma cell proliferation and suppresses angiogenesis by attenuating PI3K\/AKT\/mTOR pathway","volume":"12","author":"Qin","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2025.117923_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105659","article-title":"Facile synthesis of C1-substituted \u03b2-carbolines as CDK4 inhibitors for the treatment of cancer","volume":"121","author":"Li","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.117923_bib30","article-title":"DHW-221, a dual PI3K\/mTOR inhibitor, overcomes multidrug resistance by targeting P-Glycoprotein (P-gp\/ABCB1) and akt-mediated FOXO3a nuclear translocation in non-small cell lung cancer","volume":"12","author":"Liu","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2025.117923_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128663","article-title":"Design, synthesis, and biological evaluation of \u03b2-carboline 1,3,4-oxadiazole based hybrids as HDAC inhibitors with potential antitumor effects","volume":"64","author":"Tian","year":"2022","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2025.117923_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114095","article-title":"Discovery of novel \u03b2-carboline derivatives as selective AChE inhibitors with GSK-3\u03b2 inhibitory property for the treatment of alzheimer's disease","volume":"229","author":"Liu","year":"2022","journal-title":"Eur. J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425006889?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425006889?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T04:48:04Z","timestamp":1776919684000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425006889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":32,"alternative-id":["S0223523425006889"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117923","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and synthesis of Riluzole-Ciprofloxacin hybrids as selective MST3 inhibitors for cancer treatment","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117923","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117923"}}